Q1’ 2021 HIGHLIGHTS AND FINANCIALS

JAN H. EGBERTS, CHAIRMAN OF THE BOARD
PETER BRAUN, CEO
MARCO RENOLDI, COO
MALENE BRONDBERG, CFO

Nordic Nanovector ASA
Kjelsåsveien 168 B, 0884 Oslo, Norway
www.nordicnanovector.com
IR contact: IR@nordicnanovector.com

Forward-looking statements

This slide presentation contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.This presentation is for information purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by the Company. The information and opinions in this presentation is provided as at the date hereof and subject to change without notice. It is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the Company’s financial or trading position or prospects. This presentation does not constitute investment, legal, accounting, regulatory, taxation or other advice and does not take into account your investment objectives or legal, accounting, regulatory, taxation or financial situation or particular needs. You are solely responsible for forming your own opinions and conclusions on such matters and for making your own independent assessment of the Company. You are solely responsible for seeking independent professional advice in relation to the Company. No responsibility or liability is accepted by any person for any of the information or for any action taken by you or any of your officers, employees, agents or associates on the basis of such information.

NORDIC NANOVECTOR

Highlights – Positioning Nordic Nanovector for success

- Successful Private Placement (Feb) and oversubscribed Repair Offering (Apr) raised ~NOK 422 million (~USD 49.7 million) in gross proceeds
  - Extends the company's cash runway into H2’2022
- Protocol changes and improved execution have strengthened PARADIGME recruitment, despite COVID
- Promising Phase 1b data from the Archer-1 study evaluating Betalutin® together with rituximab in 2L FL
- Board changes
  - Hilde Hermansen Steineger decided not to stand for re-election at AGM
  - Solveig Hellebust appointed Non-executive Director at the AGM on 28 April 2021
- Peter L Braun appointed as CEO (March)

Introduction to Peter

- Close to 30 years at Hoffmann-La-Roche (“Roche”)
  - Led the Lifecycle Management teams for the successful targeted cancer therapies Herceptin® (trastuzumab) and Tarceva® (erlotinib)
  - Multiple brand launches including Herceptin, MabThera, Avastin and numerous others in onco-hematology and beyond
  - Expertise across multiple strategic and operational roles including development, manufacturing, business development and market access for innovative products
  - Held various operational leadership positions including country general manager and multiple commercial leadership roles in Europe, US and Latin America
- Served as Chief Commercial Officer for a young artificial intelligence (AI)-driven life sciences start-up and as strategy consultant to emerging healthcare companies
- Started 6 April 2021, based in Zug, Switzerland

Why I joined Nordic Nanovector

- Radiopharmaceuticals have a key role to play in the future of cancer therapy
  - A previously underappreciated modality
  - Increasing interest based on better targeting, better efficacy, better safety profiles
- Betalutin® is an important and exciting product opportunity
- One of the most attractive and advanced radiopharmaceuticals in clinical development
  - Data is compelling and suggests it has significant potential in treating NHL patients, starting with the ~70% of 3L+ FL patients who are elderly/frail, resistant or refractory to anti-CD20 immunotherapy
  - Safety profile and one-time administration bring clear clinical benefits
  - Significant progress made in executing PARADIGME
- Multiple opportunities to expand market for Betalutin® and build on the company's established heritage in radiopharmaceuticals
  - Exploring how to leverage this into the future

Our focus on NHL given its high unmet need

- Nordic Nanovector's mission is to develop innovative targeted therapies for haematological cancers
- NHL is a common cancer, impacting more than 150,000* new patients every year
- Unmet medical need in NHL is still high in both aggressive and indolent sub-types, in particular in the relapsed setting, despite more therapies being recently available
- Betalutin®'s clinical development program is most advanced in the treatment of relapsed/refractory Follicular Lymphoma
  - 40-60% indolent NHL patients treated with rituximab-containing regimen (standard of care) are refractory or develop resistance within 5 years
  - Elderly R/R FL patients may not tolerate – due to age or co-morbidities – chemotherapy or other novel agents (targeted and cell therapies) which, while effective, are associated with a high side-effect burden
  - Betalutin® is in a unique position to meet the clear need for a chemo-free, effective yet tolerable treatment, and its convenient administration schedule has QoL advantages in particular for frail patients

* Number of Diagnosed Incident Cases of NHL in the key 7 markets

Elderly and frail relapsed/refractory patients represent one of the highest unmet needs in the treatment of FL



Management of 3L FL patients is dependent on many factors, including patient age, performance status and co-morbidities, goals of therapy, number, type and response to prior therapies

Betalutin® could fill the unmet need in this population across lines of therapy



Management of 3L FL patients is dependent on many factors, including patient age, performance status and co-morbidities, goals of therapy, number, type and response to prior therapies

Positioning of Betalutin® resonates with customers

- **Efficacy** observed in LYMRIT 37-01 – Part A is seen as a **strength**
  - The **response rate** and **mDoR in complete responders** are viewed as **compelling by HemOncs***
- **The combination of potential benefits** is what sets Betalutin® apart
  - **One-time treatment + durable efficacy + manageable toxicity + simplicity for patients and physicians**
- HemOncs view **frail/elderly patients** with **co-morbidities** (that prevent chemotherapy or targeted therapies with high side-effect burden), including patients **refractory to RTX/anti-CD20,** as Betalutin®'s **ideal patients**
- Based on data from LYMRIT 37-01 Part A, EU & US payers rate Betalutin®'s **level of therapeutic improvement** as **Moderate to Important**

*Hematologists-Oncologists

BETALUTIN® - PROMISING CLINICAL DATA IN FL

Nordic Nanovector ASA
Kjelsåsveien 168 B, 0884 Oslo, Norway
www.nordicnanovector.com
IR contact: IR@nordicnanovector.com

LYMRIT 37-01 – Part A: One dose of Betalutin® reduced tumour size in 90% of evaluable patients

^{177}Lu-lilotomab satetraxetan is a promising single-administration radioimmunotherapy that produces durable responses with manageable toxicity in heavily pretreated patients with relapsed/refractory indolent NHL



*increase in tumor size truncated at 100%

Kolstad et. al. Blood Advances 2020; 4(17) p4091-4101

NORDIC NANOVECTOR

LYMRIT 37-01 – Part A: Promising efficacy in R/R FL and MZL

Compelling response rate in FL and MZL patients from a single administration

	ORR	CR
All patients (n=74)	61%	30%
All FL patients (n=57)	65%	30%
FL with ≥2 prior therapies (n=37)	**70%**	**32%**
RTX-refractory FL (n=26)	58%	19%
RTX-refractory FL, ≥2 prior therapies (n=21)	**67%**	**24%**
	ORR	**CR**
MZL (n=9)*	78%	44%

mDoR and mPFS*

Median DoR:

- 13.6 months for all responders (n=45)
- 32.0 months for complete responders (n=22)
- Median follow-up for responders of 30 months

Median PFS:

- 8.8 months overall (n=74)
- 9 months in patients with FL (n=57)

** Kolstad et al. Blood Advances, vol. 4, issue 17, 2020 (FL data); Kolstad A, et al. Abstract 2879, ASH 2018 (MZL data), PFS - Progression Free Survival, DoR – Duration of Response*

NORDIC NANOVECTOR

LYMRIT 37-01 – Part A: Well-tolerated and ‘benign’ safety profile in elderly and frail patient population

Patient characteristics (n=74)

- Elderly (median **68** years)
- Heavily pre-treated with advanced-stage disease at baseline
- Primarily FL (n=57) with other NHL types (n=17)

Betalutin® was well tolerated

- Most common grade 3/4 AEs were transient and reversible neutropenia and thrombocytopenia
- Serious AEs occurred in 14 patients (19%)
- No cases of febrile neutropenia, low incidence of platelet transfusion and no study related deaths

* *Kolstad et al. Blood Advances, vol. 4, issue 17, 2020*

PARADIGME: designed to determine the value of Betalutin® in 3L Follicular Lymphoma

- **Patient population**: 3rd-line (3L) Follicular Lymphoma (FL) patients who are refractory to anti-CD20 therapy – difficult-to-treat population, typically >70 years of age, fragile, bulky disease and often with serious co-morbidities
- **Primary endpoint**: Overall response rate (ORR)
- **Secondary endpoints**: Duration of response (DoR), Progression free survival (PFS), Overall survival (OS), Quality of life (QoL)



- 83 patients were enrolled as of 25 May 2021
- Trial reduced to 120 patients
- 95 sites in 24 countries open for enrolment

NORDIC NANOVECTOR

Improved trial execution is delivering results, despite COVID-19 restrictions have softened the growth curve

- Decision to make PARADIGME a single-arm trial has led to a reduction in patient numbers (now 120 in total) required to complete PARADIGME and for BLA filing
- Protocol amendments have now been implemented following approval in all 24 participating countries
  - Betalutin® benign safety profile has enabled us to broaden the inclusion criteria, increasing the pool size of eligible patients by est. 30–50%
- Site-specific action plans have been implemented
- Specialist U.S. recruitment firm appointed to focus on further improving
- Vaccination roll out is expected to reduce restrictions imposed by COVID-19, particularly in relation to patients having access to hospitals
  - Major benefit still to come in Europe where COVID situation is improving more slowly than anticipated
  - Implementation of ESMO watch and guidelines were clearly apparent in recent months
  - Uplift in interest to enrol patients in other regions where COVID-19 is under better control
- Reconfirm to complete patient recruitment allowing for top line 3-month results by end 2021

BLA – Biologics License Application; CRO – Contract Research Organisation

Clear regulatory strategy to gain rapid approval

- BLA filing with FDA for Accelerated Approval based on:
  - PARADIGME data, and
  - Initiation of confirmatory Phase 3 trial
- Orphan Drug Designation for 3L FL granted in US and EU in 2014
  - Fast-track designation granted in the US in June 2018 for 3L FL (and in June 2020 for R/R MZL)

FDA – US Food and Drug Administration

BETALUTIN® - ARCHER-1 PROMISING PHASE 1B DATA

Nordic Nanovector ASA
Kjelsåsveien 168 B, 0884 Oslo, Norway
www.nordicnanovector.com
IR contact: IR@nordicnanovector.com

Archer-1 (Phase Ib): Betalutin® + rituximab in R/R FL

- **Patient population**: FL (grade I-IIIA) ≥1 prior regimens
- **Primary objective**: To evaluate the safety and tolerability of Betalutin® together with RTX
- **Secondary objective**: To evaluate the preliminary anti-tumour activity of combination treatment regimen



- Seven out of seven patients achieved a response (5 CR and 2 PR)
- Assessing best approach to develop Betalutin® for the large 2L FL patient population

NORDIC NANOVECTOR

FINANCIALS

Nordic Nanovector ASA
Kjelsåsveien 168 B, 0884 Oslo, Norway
www.nordicnanovector.com
IR contact: IR@nordicnanovector.com

Good cost control



- Operating results NOK -101.2 million (Q1 20: NOK -125.9 million)



- Net cash from operating activities NOK -133.5 million (Q1 20: NOK -116.0 million)

NORDIC NANOVECTOR

Cash runway extended into H2'2022





- Net cash from operating activities of NOK -133.5 million (Q1 20: NOK -116.0 million)
- Net cash flow from investing activities of NOK -0.05 million (Q1 20: NOK 0.05 million)
- Net cash flow from financing activities of NOK 337.9 million (Q1 20: NOK -3.5 million)
- Effects of exchange rate changes on cash and cash equivalents NOK -0.4 million (Q1 20: NOK 32.9 million)
- Cash and cash equivalents amounted to NOK 498 million end of March 2021
- Successful Private Placement (Feb) and oversubscribed Repair Offering (Apr) raised ~NOK 422 million (~USD 49.7 million) in gross proceeds

* USD/NOK 10.49
** USD/NOK 8.54

1) Net cash flow from operating, investing and financing activities plus/minus currency effect

NORDIC NANOVECTOR

WE INTEND TO DELIVER SIGNIFICANT VALUE FROM BETALUTIN® AND OUR RADIOPHARMACEUTICAL EXPERTISE



Nordic Nanovector ASA
Kjelsåsveien 168 B, 0884 Oslo, Norway
www.nordicnanovector.com
IR contact: IR@nordicnanovector.com

Nordic Nanovector – Well Positioned to Win

- Radiopharmaceuticals have a key role to play in the future of cancer therapy
- Betalutin® is an important and exciting product opportunity – one of the most attractive and advanced radiopharmaceuticals in clinical development
- Focused on completing PARADIGME – targeting preliminary 3-month top-line data by end 2021
- Multiple opportunities to expand market for Betalutin® and build on both our proprietary anti-CD37 antibody franchise and our established heritage in radiopharmaceuticals

Financial calendar*

Q2 and H1'2021 results	**27 August 2021**
Q3 results	**18 November 2021**

*Dates subject to change. The time and location of the presentations will be announced in due time.

- A two-week quiet period takes place ahead of full year and quarterly results
- Please send Investor Relations enquiries to ir@nordicnanovector.com

NORDIC NANOVECTOR

THANK YOU

QUESTIONS?

Nordic Nanovector ASA
Kjelsåsveien 168 B, 0884 Oslo, Norway
www.nordicnanovector.com
IR contact: IR@nordicnanovector.com